PQ 319
319. Deputy Ken O'Flynn asked the Minister for Health to provide the eligibility criteria, prescribing settings, and clinical governance requirements applying to the managed access system under which liraglutide (Saxenda) is reimbursed under the General Medical Services and Drugs Payment Schemes; and to provide the number of patients approved under this pathway in each of the years 2024 and 2025, and to date in 2026. [10658/26]
Introduced
11 February 2026
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
11 February 2026
Summary
319. Deputy Ken O'Flynn asked the Minister for Health to provide the eligibility criteria, prescribing settings, and clinical governance requirements applying to the managed access system under which liraglutide (Saxenda) is reimbursed under the General Medical Services and Drugs Payment Schemes; and to provide the number of patients approved under this pathway in each of the years 2024 and 2025, and to date in 2026. [10658/26]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Departmental Schemes
Departmental Schemes
xml · EN · 11 February 2026
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2026-02-11/319/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2026-02-11/pq_319